Functional Variant of C-689T in the Peroxisome Proliferator-Activated Receptor-γ2 Promoter is Associated with Coronary Heart Disease in Chinese Nondiabetic Han People

• Published in: Chinese medical sciences journal Vol. 32; no. 3; pp. 177 - 184
• Main Authors: Li, Jianping, Fu, Yongping, Chang, Wenxiu, Yi, Changrong, Liu, Lihua, Xing, Haiyan
• Format: Journal Article
• Language: English
• Published: China Elsevier B.V 27.09.2017; Department of Cardiovascular Internal Medicine, Affiliated Hospital of Shaoxing University, Xiaoxing, Zhejing 312000, China%Laboratory of Molecular Biology,Medical College of Shaoxing University, Shaoxing, Zhejiang 312000, China%Department of Statistics, Medical College of Shaoxing University, Shaoxing, Zhejiang 312000, China
• Subjects: coronary heart disease; peroxisome proliferator-activated receptor-2; PPARγ; single nucleotide polymorphism; 中国汉族人; 冠心病; 启动子; 基因型频率; 等位基因频率; 过氧化物酶体增殖物激活受体; 限制性片段长度多态性; single nucleotide polymorphism; coronary heart disease; peroxisome proliferator-activated receptor-2
• DOI: 10.24920/J1001-9294.2017.042
• ISSN: 1001-9294

Objective To investigate the association between the polymorphism of C-689T in the peroxisome proliferator-activated receptor-γ2 （PPARγ2） promoter and coronary heart disease （CHD）. Methods This case-controlled study was conducted in nondiabetic Chinese Han people, which enrolled 455 patients with CHD （cases） and 693 subjects without CHD （controls）. Data of clinical indexes were collected, including height, body weight, waist circumstance, systolic blood pressure （SBP）, diastolic blood pressure （DBP）, smoking, drinking, physical activity, as well as body mass index （BMI）. Fasting blood glucose （FBG）, plasma total cholesterol （TC） and triglyceride （TG） levels were measured. Polymerase chain reaction-restricted fragments length polymorphism （PCR-RFLP） was used to determine the PPARγ2 promoter C-689→T substitution. The genotype distribution of PPARγ2 promoter C-689T, allelic frequency, clinical indexes, and laboratorial measurements were compared between the two groups. The effect of genotype on the risk of CHD was assessed using univariate and multivariate regression model. Results The genotype frequencies of CC, CT and TT in PPARγ2 promoter C-689T were 89.7%, 9.9% and 0.4% in the case group, and 93.1%, 6.6% and 0.3% in the control group, respectively （CC vs. CT＋TT, χ^2= 6.243, P=0.041）. Carriers of -689T allele （n=95） had significantly higher TC level than non-carriers （n=1053） （5.12±1.26 vs. 4.76±1.22 mmol/L, P=0.001）. Male carriers of -689T allele （n=51） were significantly higher in waist circumference, body weight, TC and TG than male non-carriers （n=656） （all P〈0.05）. In subjects whose BMI was over 25 kg/m2, carriers of -689T allele （n=82） had significantly higher levels of waist circumference, BMI, SBP and TC than non-carriers （n=231） （all p〈0.05）. The -689T allele was an independent risk factor for CHD （OR=1.668, 95%CI： 1.031-2.705, P=0.037） after adjusting for age, gender, waist circumference, body weight, BMI, smoking, physical activities, SBP, DBP, FBG, TC and TG level. Conclusion These data support the hypothesis that the -689T allele is associated with an increased risk of CHD, in Chinese Han people and correlates significantly with the profiles of CHD-related risk factors.